FDA Authorizes Extended-Release Injection for HIV Prevention
The U.S. Food and Drug Administration has given the green light to lenacapavir, a biannual injectable medication that offers formidable protection against HIV. A publication has already touted it as a standout innovation for 2024.
Clinical trial results demonstrate lenacapavir's 99.9 percent success rate in preventing sexually transmitted HIV infections for individuals over 35 kilograms. This antiretroviral drug works not by boosting the immune system, but by halting the virus's replication at an early stage. It achieves this by disrupting the capsid protein of the virus, provided the injections are received every six months.
A New Development in HIV Prevention
While lenacapavir has been available in some countries as a treatment for forms of HIV resistant to other therapies, its preventive application hadn't been sanctioned until now. The FDA’s approval marks a pivotal point in the ongoing battle against the HIV/AIDS epidemic.
Previous preventive measures like pre-exposure prophylaxis (PrEP) pills exist, requiring daily administration and consistent adherence. Lenacapavir's extended effectivity could simplify maintaining protection against HIV.
Market Introduction and Financial Considerations
Gilead Sciences, the developer, intends to introduce lenacapavir under the brand name Yeztugo and plans to produce 10 million doses by 2026. Daniel O’Day, CEO of Gilead, lauded the drug as a significant scientific achievement in the HIV epidemic fight.
Notwithstanding its promise, the price of lenacapavir could impede access. In the U.S., Yeztugo's yearly cost stands at $28,218 per individual. Winnie Byanyima, from the Joint United Nations Program on HIV/AIDS, highlighted the financial hurdles faced by those in Africa, where the drug could have substantial impact as most people living with HIV are located in sub-Saharan Africa.
Access Strategy and Potential Solutions
Gilead is working on a global accessibility strategy for lenacapavir but has yet to disclose specifics. One potential avenue is 'voluntary licensing,' allowing other companies to produce affordable generic versions for low-income countries, with research suggesting an annual supply could cost as little as $25.



Leave a Reply